A CanSino Biologics employee works on the production of the recombinant Covid-19 vaccine in September. Photo: Getty Images
A CanSino Biologics employee works on the production of the recombinant Covid-19 vaccine in September. Photo: Getty Images

CanSino Biologics CEO Yu Xuefeng says mRNA vaccines are key to China’s coronavirus fight

  • China has yet to approve any mRNA vaccines, which have a much higher efficacy rate than ones made using older forms of technology
  • CanSino Biologics has started a clinical trial in Beijing, and the World Health Organization has approved its viral vector vaccine for emergency use

A CanSino Biologics employee works on the production of the recombinant Covid-19 vaccine in September. Photo: Getty Images
A CanSino Biologics employee works on the production of the recombinant Covid-19 vaccine in September. Photo: Getty Images
READ FULL ARTICLE